Aveanna Healthcare Holdings, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 30, 2023 (52 weeks), compared with the 52-week fiscal year ended December 31, 2022. This filing reports annual results; it does not provide a clear standalone fourth-quarter income statement.
Business context
Aveanna provides home-based care and related products across three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). PDS is predominantly Medicaid-funded and accounts for most revenue; HHH is primarily Medicare-reimbursed.
Financial and operating performance
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $1,895.2 million | $1,787.6 million |
| Gross margin | $595.4 million; 31.4% | $553.2 million; 30.9% |
| Operating income (loss) | $8.1 million; 0.4% of revenue | $(642.3) million; (35.9%) |
| Net loss | $(134.5) million; $(0.71) per share | $(662.0) million; $(3.57) per share |
| Adjusted EBITDA (non-GAAP) | $139.2 million | $129.3 million |
| Net cash from operating activities | $22.7 million | $(48.4) million |
Revenue rose 6.0%. PDS revenue increased 7.3% to $1,518.8 million, reflecting 3.5% higher care hours and a 3.8% higher revenue rate. MS revenue grew 12.7% to $157.8 million, on 8.8% patient growth and a 3.9% higher revenue rate. HHH revenue declined 6.0% to $218.6 million; total home-health admissions fell 18.2% and episodes fell 6.2%, while revenue per completed episode rose 1.5%.
Field contribution, a non-GAAP measure, increased 19.6% to $234.5 million (12.4% margin versus 11.0%). Gross margin improvement and lower branch and regional administrative expense as a share of revenue contributed to the increase. The much smaller GAAP operating loss versus 2022 primarily reflects goodwill impairment falling to $105.1 million from $675.3 million, rather than a comparable change in underlying operating profit.
Interest expense, net, increased 42.9% to $152.9 million, reflecting higher rates and greater securitization borrowings. Other income fell to $5.9 million from $85.5 million, largely because of lower non-cash derivative valuation gains.
Debt, liquidity and balance sheet
At December 30, 2023, principal debt under term loans and the securitization facility totaled approximately $1.470 billion; the weighted-average interest rate was 10.1%. Cash was $43.9 million, with $20.0 million available under the securitization facility and $168.1 million of revolving-credit borrowing capacity, subject to facility terms and covenants. The company reported compliance with financial covenants at year-end and stated that available cash, facility capacity and operating cash flows should cover requirements for at least 12 months.
FY2023 investing cash use was $8.8 million and financing cash provided was $10.8 million. Total liabilities were $1.740 billion, exceeding total assets of $1.613 billion; stockholders’ deficit was $129.6 million. Goodwill and intangible assets totaled approximately $1.149 billion, about 71% of assets. Term-loan principal maturities include $862.95 million in the fiscal year ending December 30, 2028; the second-lien loan matures in 2029.
Material changes, outlook and risks
- Margins and labor: Management cited operational efficiencies and improved margins, but caregiver shortages and wage inflation remain constraints. PDS cost of revenue per hour increased 3.6%, approximately alongside its 3.8% revenue-rate increase.
- Reimbursement outlook: The 2024 home-health rule includes a 3.3% market-basket update and a phased permanent behavioral adjustment; 2.89% was applied to the base 30-day payment rate beginning January 1, 2024. The filing cautions that the adjustment may adversely affect results. National expanded Home Health Value-Based Purchasing is in effect; performance data from 2023 first affects payment in 2025.
- Liquidity and claims disruption: A February 2024 Change Healthcare cybersecurity incident disrupted submission of certain claims through third-party vendors. At the filing date, approximately 16 business days of billings for certain claims were affected; management warned of possible higher receivables and lower first-quarter 2024 operating cash flow, with working-capital needs expected to be funded from cash and facility draws.
- Internal controls: Management and EY concluded internal control over financial reporting was ineffective at year-end because of a material weakness in IT general controls and related business-process controls, including controls dependent on a PDS revenue system. No financial-statement misstatement was identified; remediation was underway, including a new revenue system planned for Q1 2024. EY issued an adverse opinion on internal controls but an unqualified opinion on the financial statements.
- Impairment and contingencies: The company recorded a $105.1 million HHH goodwill impairment in 2023 after labor-market challenges limited anticipated volume. It disclosed a $7.9 million arbitration award under appeal, supported by a $9.1 million appellate bond, and DOJ inquiries concerning nurse wages/hiring and hospice billing and referral-payment allegations. Management said losses were not considered probable for the investigations, but their outcomes and any loss ranges could not be predicted.
- Other regulatory exposure: Medicare and Medicaid rate changes, managed-care contracting and payment delays, billing/documentation audits, EVV compliance, cybersecurity, clinician availability, and substantial variable-rate debt are key risks. A proposed Medicaid rule would require at least 80% of certain personal-care payments to go to direct-care-worker compensation; its final form and impact were uncertain.
- Guidance: The supplied filing text does not provide a clear numeric company-wide FY2024 forecast. Management’s stated liquidity view is not a guarantee of future cash generation or refinancing access.
Investor facts to verify
- Progress and independent testing of the material-weakness remediation, especially the replacement PDS revenue system and IT access/change-management controls.
- How quickly Change Healthcare claim processing recovered, the amount of any receivables buildup, and the effect on 2024 operating cash flow and facility usage.
- Debt-service capacity at the reported 10.1% weighted-average rate, covenant headroom, and plans for the large 2028 term-loan maturity.
- Whether HHH admissions stabilize and whether labor availability, reimbursement changes, and value-based purchasing affect volumes and margins.
- Developments in the DOJ inquiries, arbitration appeal, other litigation, and any further goodwill impairment indicators.